GLAXOSMITHKLINE PHARMACEUTICALS
Quarterly Results Analysis [Sep2024]
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,011 Cr | ₹815 Cr | ₹930 Cr | ₹805 Cr | ₹957 Cr | ₹762 Cr | ₹787 Cr | ₹802 Cr |
Expenses | ₹689 Cr | ₹584 Cr | ₹673 Cr | ₹587 Cr | ₹668 Cr | ₹618 Cr | ₹618 Cr | ₹574 Cr |
Operating Income | ₹322 Cr | ₹231 Cr | ₹257 Cr | ₹218 Cr | ₹289 Cr | ₹144 Cr | ₹170 Cr | ₹229 Cr |
Other Income | ₹35 Cr | ₹36 Cr | ₹30 Cr | ₹28 Cr | ₹28 Cr | ₹36 Cr | ₹28 Cr | ₹23 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
Depreciation | ₹17 Cr | ₹16 Cr | ₹18 Cr | ₹17 Cr | ₹18 Cr | ₹16 Cr | ₹17 Cr | ₹16 Cr |
Profit Before Tax | ₹344 Cr | ₹249 Cr | ₹271 Cr | ₹65 Cr | ₹299 Cr | ₹181 Cr | ₹190 Cr | ₹224 Cr |
Profit After Tax | ₹253 Cr | ₹182 Cr | ₹194 Cr | ₹46 Cr | ₹218 Cr | ₹132 Cr | ₹133 Cr | ₹165 Cr |
EPS | ₹14.90 | ₹10.76 | ₹11.48 | ₹2.70 | ₹12.84 | ₹7.81 | ₹7.88 | ₹9.71 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAXOSMITHKLINE PHARMACEUTICALS | -3% | -3.4% | 35.3% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 0.7% | 47.3% |
CIPLA | 0.3% | -1.8% | 19.6% |
DR REDDYS LABORATORIES | 6% | 11.8% | 20.3% |
ZYDUS LIFESCIENCES | -1.5% | -0.1% | 47% |
DIVIS LABORATORIES | -1.1% | -5.8% | 61.7% |
MANKIND PHARMA | 3.7% | 11.4% | 59.4% |
TORRENT PHARMACEUTICALS | 0.6% | 4.1% | 59.5% |
LUPIN | 3.3% | 2.9% | 75.9% |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 24.07 % |
Y-o-Y | 5.62 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹1,011 Cr | 24.07 | |
Jun2024 | ₹815 Cr | -12.38 | |
Mar2024 | ₹930 Cr | 15.47 | |
Dec2023 | ₹805 Cr | -15.85 | |
Sep2023 | ₹957 Cr | 25.65 | |
Jun2023 | ₹762 Cr | -3.28 | |
Mar2023 | ₹787 Cr | -1.85 | |
Dec2022 | ₹802 Cr | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 39.55 % |
Y-o-Y | 11.13 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹322 Cr | 39.55 | |
Jun2024 | ₹231 Cr | -10.39 | |
Mar2024 | ₹257 Cr | 17.98 | |
Dec2023 | ₹218 Cr | -24.67 | |
Sep2023 | ₹289 Cr | 101.20 | |
Jun2023 | ₹144 Cr | -15.24 | |
Mar2023 | ₹170 Cr | -25.78 | |
Dec2022 | ₹229 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 12.47 % |
Y-o-Y | 5.22 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 31.83% | 12.47 | |
Jun2024 | 28.3% | 2.28 | |
Mar2024 | 27.67% | 2.18 | |
Dec2023 | 27.08% | -10.48 | |
Sep2023 | 30.25% | 60.14 | |
Jun2023 | 18.89% | -12.38 | |
Mar2023 | 21.56% | -24.38 | |
Dec2022 | 28.51% | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 38.49 % |
Y-o-Y | 16.09 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹253 Cr | 38.49 | |
Jun2024 | ₹182 Cr | -6.25 | |
Mar2024 | ₹194 Cr | 325.37 | |
Dec2023 | ₹46 Cr | -78.98 | |
Sep2023 | ₹218 Cr | 64.47 | |
Jun2023 | ₹132 Cr | -0.88 | |
Mar2023 | ₹133 Cr | -18.92 | |
Dec2022 | ₹165 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 11.62 % |
Y-o-Y | 9.90 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 24.98 % | 11.62 | |
Jun2024 | 22.38 % | 6.98 | |
Mar2024 | 20.92 % | 268.31 | |
Dec2023 | 5.68 % | -75.01 | |
Sep2023 | 22.73 % | 30.93 | |
Jun2023 | 17.36 % | 2.48 | |
Mar2023 | 16.94 % | -17.41 | |
Dec2022 | 20.51 % | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 38.48 % |
Y-o-Y | 16.04 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹14.9 | 38.48 | |
Jun2024 | ₹10.76 | -6.27 | |
Mar2024 | ₹11.48 | 325.19 | |
Dec2023 | ₹2.7 | -78.97 | |
Sep2023 | ₹12.84 | 64.40 | |
Jun2023 | ₹7.81 | -0.89 | |
Mar2023 | ₹7.88 | -18.85 | |
Dec2022 | ₹9.71 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD